Floatz logo

Zanidatamab

Locally Advanced Rectal Cancer (LARC)

Emory Universitymonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

69 Active assets in the Locally Advanced Rectal Cancer (LARC) cohort.

Asset / SponsorPhaseRating
Irinotecan
Sun Yat-sen University
Phase 4BBB
FLUOROURACILUM
Seoul National University Hospital
Phase 3BBB
Eloxatin
Sun Yat-sen University
Phase 3BBB
Irinotecan
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Capecitabine
Tao Zhang
Phase 3BB

View all 50 →

Same molecule, other indications

Zanidatamab is also rated in:

HER2 positive breast carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
HER2 Low Breast CarcinomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →